VivoSeq
Other

Igan

0

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

IgAN is an early-stage landscape with 0 programs across 7 companies. The most active players are Johnson & Johnson, AbbVie, Celyad Oncology SA.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalC

Celyad Oncology SA

0 programs

PreclinicalV

Vera Therapeutics, Inc.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalT

Travere Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

27

clinical trials

Completed22 · 81%
Not yet recruiting2 · 7%
Unknown status2 · 7%
Recruiting1 · 4%

Clinical Trials

Trial Activity

27 trials

Monthly Dosing of Atacicept in IgAN
Recruiting·VVera Therapeutics, Inc.·Phase 2·NCT07020923·90 enrolled
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
Not yet recruiting·PPeking University First Hospital·Phase 2·NCT07282197·40 enrolled
A Safety Study of 212Pb-Pentixather Radioligand Therapy
Not yet recruiting·—·Phase 1·NCT05557708·20 enrolled
A Study of LUMIGAN® RC in the Clinical Setting
Completed·AbbVie logoAbbVie·Phase 4·NCT01833741·1,137 enrolled
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
Completed·MMaruho Co., Ltd.·Phase 3·NCT02576847·307 enrolled
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT03270579·8 enrolled
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Completed·CCelyad Oncology SA·Phase 1·NCT02203825·12 enrolled
Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies
Completed·UUniversity Hospital, Lille·N/A·NCT02902016·22 enrolled
Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers
Completed·MMaruho Co., Ltd.·Phase 1·NCT03071679·16 enrolled
Comparison of Antimicrobial Action of Sodium Hypochlorite and Polyhexamethylene Biguanide as Root Canal Irrigants
Completed·—·Phase 2·NCT05306431·60 enrolled
Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice
Completed·HHordinsky, Maria K., MD·Phase 1·NCT00177099·35 enrolled
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT02169973·15 enrolled
Specific PET Radioligand Binding to Translocator Protein
Completed·National Institute of Mental Health (NIMH)·Phase 1·NCT02181582·32 enrolled
Evaluation of a Novel PET Radioligand to Image OGA
Completed·National Institute of Mental Health (NIMH)·N/A·NCT03632226·28 enrolled
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT04911543·13 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)